The final piece of Novartis’ ambitious U.S. manufacturing “Mosaic” is now in place with the announcement of a new 56,200-square-foot active pharmaceutical ingredient (API) facility in Morrisville, North Carolina.
The project marks the seventh new facility announced within roughly one year of the company’s landmark $23 billion, five-year U.S. investment plan unveiled in April 2025. With this addition, Novartis is significantly advancing its goal of achieving robust end-to-end domestic production for key medicines.
The Morrisville site will focus on manufacturing APIs for solid dosage forms (tablets and capsules) as well as RNA therapeutics — a critical capability as the company expands its next-generation platforms. Unlike traditional large-scale plants, this facility operates as a versatile, high-density node that integrates tightly with Novartis’ growing Research Triangle presence.
A Flagship Hub Takes Shape in North Carolina
This new API plant forms part of Novartis’ broader flagship manufacturing hub across Durham and Morrisville. When fully operational between 2027 and 2028, the hub will span more than 700,000 square feet and support end-to-end production — from active ingredients through finished medicines — for multiple therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular diseases.
The $771 million North Carolina investment (announced late 2025) nearly doubles Novartis’ footprint in the state and is expected to create up to 700 new jobs by 2030. In Morrisville specifically, the company now has two dedicated facilities: the new API plant and an earlier-announced solid dosage production and packaging site, reflecting a combined local commitment of approximately $231 million in Wake County.
By 2028, Novartis will transform the Research Triangle into a central pillar of its U.S. operations. The site will work in concert with other domestic facilities, including radioligand therapy centers in Texas and Florida, cell and gene therapy hubs in New Jersey and Durham, and expanded R&D laboratories.
Strategic Significance: True Onshoring
What sets this announcement apart is its role in completing a true U.S.-based supply chain mosaic. For the first time, Novartis will have strengthened end-to-end manufacturing control across its advanced platforms — small molecules, large molecules/biologics, RNA, and cell/gene therapies — largely insulated from global logistics risks, raw material disruptions, and also geopolitical tensions that have exposed vulnerabilities in pharmaceutical supply chains in recent years.
This shift mirrors a wider industry trend: moving away from reliance on centralized overseas API production toward agile, regionally interconnected “hubs” that prioritize speed, quality control, and resilience. The inclusion of RNA therapeutics API capability at Morrisville is particularly noteworthy, as demand for RNA-based medicines continues to grow.
Also, this move by Novartis fits into a broader, high-stakes shift in the American industrial landscape. We are seeing a coordinated effort to ‘onshore’ critical capabilities, exemplified by the BioMADE Biomanufacturing Facility in Maple Grove. Funded in part by the DoD, the Maple Grove site is explicitly built to secure domestic self-sufficiency for industrial precursors and energetics.
“Novartis’ investment is a strong step toward making drugs for Americans in America,” noted North Carolina officials during earlier groundbreaking events for the hub — a sentiment that resonates even more clearly now that the final piece is on the board.
Additionally, with construction progressing rapidly, the Morrisville API facility is expected to come online as part of the hub’s 2027–2028 target. For Novartis, this completes a rapid transformation of its U.S. infrastructure. For the broader biopharma sector, it underscores that onshoring is no longer aspirational — it is actively taking shape, one specialized facility at a time.
Novartis Morrisville API Facility: Project Factsheet
- Location: Morrisville, Wake County, North Carolina
- Facility Size: 56,200 square feet
- Project Type: Greenfield manufacturing facility
- Core Technical Function: Production of Active Pharmaceutical Ingredients (API)
- Technology Platforms: RNA therapeutics and solid dosage (tablets/capsules)
- Wake County Investment: $231 million (initial commitment)
- Total Regional CapEx: $771 million (combined Durham and Wake County hubs)
- National Strategic Status: 7th and final facility of the $23 billion U.S. investment plan
- Operational Target: Fully integrated and “go-live” status by 2027–2028
- Manufacturing Capability: Enables end-to-end U.S. production for Small Molecule, Large Molecule, RNA, RLT, and Cell & Gene platforms
- Economic Impact: Contributing to 700 new regional jobs by 2030
- Regional Ecosystem: Works in tandem with the 700,000-square-foot Durham flagship hub (ground broken December 2025)
